Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Clinical role
Concurrent reading/reporting aid; includes an initial report populated with selected findings.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Not a standalone diagnostic device and not a substitute for physician review; the MammoScreen 5 algorithm is unchanged from MammoScreen 4.
Exact FDA record: K260714 · Agent source review · . This is not clinician review or local acceptance.
Within this record's scope
Consider for concurrent review of screening FFDM or DBT from systems compatible with this MammoScreen 5 record.
Limits to check
Physician interpretation remains required. Do not carry an older release's input rules into this release, or assume a separate density module is included.
Questions for the vendor and your team
Which release, acquisition systems, prior-image scenarios and licensed reporting functions are covered by the quote?
Can readers verify finding marks and the initial report against the original images, with an agreed correction and fallback workflow?
These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Image interpretation · source-reviewed 2026-11-05
FDA K260714 summary, page 6: concurrent mammogram interpretation and reporting aid. This role does not establish local compatibility or autonomous diagnosis.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.
Who uses it?Intended users: Physicians interpreting screening mammograms.
What does the software produce?Output: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.
What is its most important limitation?Key limitation: Not a standalone diagnostic device and not a substitute for physician review; the MammoScreen 5 algorithm is unchanged from MammoScreen 4.
Clinical takeaway. Clinical role: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Evidence takeaway. Evidence from the reviewed source record: New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.
Evidence context: questions, not a score
Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.
Existing study anchor: MammoScreen 5 standalone performance testing of newly introduced scenarios. Tested version label: MammoScreen 5.
What was tested?
MammoScreen 5 standalone testing evaluated newly introduced image/view and current/prior scenarios. Clinical documentation from MammoScreen 3 was carried forward; no additional clinical study was conducted for this submission.
Source section: 510(k) summary, Non clinical Testing and Clinical Testing
On which cases and versions?
The standalone table reports 9,789 patients/studies with biopsy and follow-up reference classifications. This is not a new 9,789-case version-5 reader trial. The admitted study anchor is MammoScreen 5 standalone testing of newly introduced scenarios; MammoScreen 3 K240301 clinical documentation is a separate carried-forward component.
Source section: 510(k) summary, Non clinical Testing and Clinical Testing
What changed?
The submission states that the algorithm did not change from MammoScreen 4 and reports scenario-level non-inferiority testing. Scenario differences include both positive and negative estimates; no single performance gain is assigned to all scenarios.
Source section: 510(k) summary, Non clinical Testing and Clinical Testing
What does this not establish?
Carryover evidence does not create a new version-5 clinical trial. Ambiguous extracted demographic totals are not converted to percentages. Exact input combinations, downstream recalls and clinical outcomes cannot be inferred from a combined score.
Source section: 510(k) summary, Non clinical Testing and Clinical Testing
Study design, population and missing context
evidence Role
Newly introduced scenario standalone evaluation, with clinical documentation carried forward from MammoScreen 3 K240301. These are separate evidence components.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
design
Standalone scenario comparisons for MammoScreen 5; no additional clinical studies conducted to support equivalence to MammoScreen 4.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Training/tuning and test data sources were separated; the reviewed table does not provide a complete training cohort description.
training · 510(k) summary, Non clinical Testing and Clinical Testing
evaluation Population
The standalone table reports 9,789 patients and 9,789 studies. Earlier MammoScreen 3 clinical-study documentation is cited separately.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
reference Standard
Positive cases biopsy-proven; benign cases use biopsy and/or imaging follow-up; negative cases verified by imaging follow-up as described in the table.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
comparator
New scenarios compared with reference scenarios previously supported by MammoScreen 4; algorithm described as unchanged from the predecessor.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
FFDM/DBT and prior-exam combinations, supplementary and duplicated views. Exact combination support must be read from the submission, not inferred across all vendors.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
sample Composition
The table reports 9,789 studies. Extracted demographic category counts do not provide a consistent complete denominator; no percentages are computed here.
validation · 510(k) summary, Non clinical Testing and Clinical Testing
sponsor Involvement
Therapixel submitted the regulatory testing package and carryover clinical documentation. This does not establish independent investigator review.
regulatory summary · 510(k) summary, Non clinical Testing and Clinical Testing
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.
Documented care setting
Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.
Modality and protocol
Screening mammograms from compatible FFDM and DBT systems; compatible prior examinations may also be used.
Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.
New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.
No version-5 sensitivity value with complete endpoint context was abstracted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No version-5 specificity value with complete endpoint context was abstracted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
MammoScreen 5 standalone performance testing of newly introduced scenarios
DesignStandalone non-inferiority comparison of newly introduced scenarios (supplementary views, duplicated views and current/prior combinations) with reference scenarios already cleared with MammoScreen 4.
Population9,789 patients and 9,789 studies from test-group data sources kept separate from training/tuning; positives biopsy-proven, benign cases verified by imaging follow-up (plus biopsy if biopsied), negatives verified by imaging follow-up.
Scopeexact submission
Tested versionMammoScreen 5
Samplen=9789
IndependenceIndependence not established
K260714
The submission states the algorithm did not change from MammoScreen 4 and no additional clinical studies were conducted; MammoScreen 3 (K240301) clinical study results are cited separately in the Clinical Testing section.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
Existing route context (at most two)
Broader supplier context
Not reviewed for this pairing
AI version: not established; system version: not established
Scope: product family; geography: Geography not established for this exact pairing
Configuration: Merge describes mammography integrations including Therapixel. The source does not identify MammoScreen 5 and a specific Merge build.
Condition: A supplier-family integration statement is context, not qualification of this FDA record or site installation.
Local test needed: Obtain the two exact builds, licensed interface and conformance/acceptance evidence from both suppliers.
Source review: 2026-11-06
Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
Installed-system acceptance has not been performed.
Public version baseline: 9.5; Public technical document; reviewed 2026-11-06.
Highest version listed in Merge's public DICOM index. Regional availability and corrected patch/build need supplier confirmation.
The reviewed FDA record identifies affected 9.5 software. Confirm the supplier's correction and exact build before acceptance.
Reference baseline only. Installed build and AI compatibility remain to be established.
Source context, not route validation: Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Current MammoScreen family documentation describes a site virtual gateway, DICOM Secondary Capture and Structured Report output, and optional EMR/reporting API integration using HL7/FHIR.
Scope: Product family. Current family documentation, not evidence that every interface or package shipped with the cleared version.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Current family documentation describes a site gateway with cloud computation and an on-premises option available on request.
Scope: Product family.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Current MammoScreen family documentation describes a site virtual gateway, DICOM Secondary Capture and Structured Report output, and optional EMR/reporting API integration using HL7/FHIR.
Product family
Checked 2026-09-06
Current family documentation, not evidence that every interface or package shipped with the cleared version.
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.
A partial mapping of MammoScreen 4 and 5 reading-aid records. Density products and other releases are not included in this mapping.
Therapixel identifies MammoScreen as its screening-mammography reading software. The manufacturer-prepared K260714 summary explicitly identifies K243679 as MammoScreen 4 and describes both as software versions of MammoScreen. This does not transfer tested input scenarios, evidence, licenses or availability between records.
K260714 · 2026-06-26. Latest decision among these mapped records only. This is not a current installed-version or supersession claim.
Latest documented release
The sources do not establish a complete current commercial release chronology.
Current commercial availability
Availability of an exact release and licensed configuration must be confirmed with the supplier.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-06Last searched
20Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored PMID 32159424 is an online breast-cancer risk decision-aid study, not MammoScreen product evidence; excluded by metadata. No trial records stored. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, vendor product page, vendor technical page, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-06 - Exact product version
No public price or contract for MammoScreen 5 was located in the reviewed vendor material.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Therapixel MammoScreen reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Therapixel's adoption page describes general US screening mammography policy; it states no coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-06 - Exact product version
No site monitoring or update-acceptance procedure was established.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.